ぶどう膜炎 - 世界市場の考察、疫学、市場予測（2034年）

主なハイライト

• 米国では、ぶどう膜炎関連疾患の増加、認知度の向上、ぶどう膜炎の診断の向上により、ぶどう膜炎の有病率が増加しています。
• 分類に向けた疾患命名法、臨床試験、ドラッグデリバリーシステム、マルチモダリティイメージング、「オミックス」技術を用いたラボ検査の進歩により、疾患の病因に関する知見が得られています。さらに、眼免疫学に対する知見は、ぶどう膜炎の病因と罹患しやすさの根底にある分子メカニズムの理解を深めることにもつながっています。
• 進行中の調査により、ぶどう膜炎の危険因子や治療戦略に対する理解が深まり、疾患管理の革新が進んでいます。
• 副腎皮質ステロイドはぶどう膜炎患者の炎症を治療する第一選択薬として使用されています。さらに、副腎皮質ステロイドで静止が得られない場合は、ステロイドを温存する薬剤として免疫調節薬が投与されます。ぶどう膜炎の極端な症例では、硝子体手術や徐放性デバイスの植込みなどの外科的介入が考慮されます。
• ぶどう膜炎の市場を理解する上での大きな懸念事項の1つは、ぶどう膜炎の日常管理で使用される多くの介入の有効性を支持するエビデンスが不足していることです。さらに、米国、欧州4ヶ国・英国、日本では、さまざまなタイプのぶどう膜炎とその関連疾患の管理に関する適切なコンセンサスガイドラインが存在しません。
• 2022年、ぶどう膜炎の市場規模は主要7市場の中で米国がもっとも大きく、約7億5,903万米ドルを占め、2034年までに拡大が予測されています。

ぶどう膜炎市場の見通し

ぶどう膜炎は、ぶどう膜管の重篤な眼内炎症性疾患であり、多くの場合、視力障害、失明、QOLの低下を伴います。多くの場合、もっとも活動的で経済的に生産性の高い時期の患者が罹患します。世界中で予防可能な失明の主因となっており、治療が十分に行われていない疾患です。

この疾患は多彩な症状を呈するため、診断と管理は困難です。炎症を抑えて完全寛解を達成し、眼合併症、永続的な蓄積障害、長期的な視力低下を軽減または回避するためには、正しい診断アプローチと適切な治療法の評価による迅速な診断が極めて重要です。治療は、感染因子を治療するか、免疫状態を治療することにより、疾患の静止を得ることを目的とします。

推奨される治療シナリオは、炎症寛解を誘導するもっとも攻撃的でない治療から始まり、より攻撃的な治療、そして最終的には炎症寛解へと進みます。治療法（投与経路を含む）の選択は、基礎診断、疾患の侵攻性、晩期性、併存疾患の有無によって異なります。また、これらの薬剤の疾患寛解を誘導する能力と、潜在的な副作用や毒性とのバランスをとることも重要です。副腎皮質ステロイド、免疫調節薬、生物学的製剤は、手術以外のさまざまな治療オプションです。

• 主要7市場のぶどう膜炎の総市場規模は、2022年に約14億6,866万米ドルであり、予測期間（2023年～2034年）に、疾患に対する認知度の向上と新治療法の上市による拡大が予測されています。
• 主要7市場の中でぶどう膜炎の市場シェアがもっとも高かったのは米国で、2022年の収益は7億5,903万米ドルであり、次いで日本、ドイツ、その他となっています。
• 欧州4ヶ国・英国の中では、ドイツが2022年に約1億1,573万米ドルと最大の市場規模を占め、スペインは2022年に約9,049万米ドルで最下位になりました。
• 日本は2022年に約1億9,662万米ドルで主要7市場の中で第2位の市場規模を占め、予測期間（2023年～2034年）に増加が見込まれます。
• ぶどう膜炎に対する現在の標準治療には、YUTIQ/ILUVIENのような副腎皮質ステロイド、黄斑浮腫に対するXIPERE、免疫抑制剤、HUMIRAのような生物学的製剤、非ステロイド性抗炎症薬などがあります。2022年の主要7市場において、2番目に高い市場シェアを獲得したのは3億4,478万米ドルの副腎皮質ステロイド薬で、そのうちYUTIQ/ILUVIENは3,234万米ドル、その他の副腎皮質ステロイド薬は3億1,244万米ドルでした。

当レポートでは、ぶどう膜炎の主要7市場（米国、ドイツ、スペイン、イタリア、フランス、英国、日本）について調査分析し、各地域の市場規模、現在の治療法、アンメットニーズ、新薬などの情報を提供しています。

目次

第1章 重要考察

第2章 レポートのイントロダクション

第3章 ぶどう膜炎市場の概要

• ぶどう膜炎の市場シェア分布（2020年）
• ぶどう膜炎の市場シェア分布（2034年）

第4章 ぶどう膜炎の疫学と市場の調査手法

第5章 ぶどう膜炎のエグゼクティブサマリー

第6章 重要な出来事

第7章 ぶどう膜炎の疾患背景と概要

• ぶどう膜炎のイントロダクション
• 分類
• 兆候と症状
• 合併症
• 病態生理学
• 診断
  • 診断アルゴリズム
  • 診断ガイドライン
• 治療
  • 治療アルゴリズム
  • 治療ガイドラインと推奨事項

第8章 ペイシェントジャーニー

第9章 疫学と患者人口

• 主な調査結果
• 前提条件と根拠
• 主要7市場のぶどう膜炎の診断された総有病者数
• 主要7市場のぶどう膜炎を伴うMEの診断された総有病者数
• 米国
• 欧州4ヶ国・英国
• 日本

第10章 上市済み薬品

• 主な競合
• XIPERE: Clearside Biomedical/Bausch+Lomb
• YUTIQ/ILUVIEN: EyePoint Pharmaceuticals/Alimera Sciences
• HUMIRA: AbbVie/Eisai
• OZURDEX: AbbVie
• RETISERT: Bausch + Lomb

第11章 新薬

• 主な競合
• TRS01: Tarsier Pharma
• Licaminlimab (OCS-02): Oculis Pharma
• Vamikibart (RO720220/RG6179): Roche/Eleven Biotherapeutics
• OLUMIANT (baricitinib): Eli Lilly and Company
• EYS606: Eyevensys
• Izokibep: Acelyrin/Affibody Medical
• Brepocitinib: Priovant Therapeutics
• OCS-01: Oculis Pharma

第12章 ぶどう膜炎：市場の分析

• 主な調査結果
• 主な市場予測の前提条件
• 市場見通し
• コンジョイント分析
• 主要7市場のぶどう膜炎の総市場規模
• 主要7市場のぶどう膜炎の市場規模：治療法別
• 米国のぶどう膜炎の市場規模
  • 米国のぶどう膜炎の総市場規模
  • 米国のぶどう膜炎の市場規模：治療法別
• 欧州4ヶ国・英国のぶどう膜炎の市場規模
  • 欧州4ヶ国・英国のぶどう膜炎の総市場規模
  • 欧州4ヶ国・英国のぶどう膜炎の市場規模：治療法別
• 日本のぶどう膜炎の市場規模
  • 日本のぶどう膜炎の総市場規模
  • 日本のぶどう膜炎の市場規模：治療法別

第13章 KOLの見解

第14章 SWOT分析

第15章 アンメットニーズ

第16章 市場参入と償還

• 米国
• 欧州4ヶ国・英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
• 日本

第17章 付録

第18章 DelveInsightのサービス内容

第19章 免責事項

第20章 DelveInsightについて

List of Tables

• Table 1: Summary of Uveitis Market and Epidemiology (2020-2034)
• Table 2: Key Events for Uveitis
• Table 3: IUSG Clinical Classification of Uveitis
• Table 4: Key Recommendations for Practice
• Table 5: First Line of Therapy for the Treatment of Uveitis, 2023
• Table 6: Evidence Levels of NCSITs in the Treatment of Noninfectious Uveitis
• Table 7: Evidence Levels of Biologic Agents in the Treatment of Noninfectious Uveitis
• Table 8: American College of Rheumatology/Arthritis Foundation Guidelines for JIA-associated Uveitis
• Table 9: Adalimumab and Dexamethasone for Treating Noninfectious Uveitis
• Table 10: Total Diagnosed Prevalent Cases of Uveitis in the 7MM (2020-2034)
• Table 11: Total Diagnosed Prevalent Cases of ME Associated with Uveitis in the 7MM (2020-2034)
• Table 12: Total Diagnosed Prevalent Cases of Uveitis in the US (2020-2034)
• Table 13: Type-specific Diagnosed Prevalent Cases of Uveitis in the US (2020-2034)
• Table 14: Diagnosed Prevalent Cases of Uveitis by Anatomical Location in the US (2020-2034)
• Table 15: Etiology-specific Diagnosed Prevalent Cases of Uveitis in the US (2020-2034)
• Table 16: Total Diagnosed Prevalent Cases of Uveitis in EU4 and the UK (2020-2034)
• Table 17: Type-specific Diagnosed Prevalent Cases of Uveitis in EU4 and the UK (2020-2034)
• Table 18: Diagnosed Prevalent Cases of Uveitis by Anatomical Location in EU4 and the UK (2020-2034)
• Table 19: Etiology-specific Diagnosed Prevalent Cases of Uveitis in EU4 and the UK (2020-2034)
• Table 20: Total Diagnosed Prevalent Cases of Uveitis in Japan (2020-2034)
• Table 21: Type-specific Diagnosed Prevalent Cases of Uveitis in Japan (2020-2034)
• Table 22: Diagnosed Prevalent Cases of Uveitis by Anatomical Location in Japan (2020-2034)
• Table 23: Etiology-specific Diagnosed Prevalent Cases of Uveitis in Japan (2020-2034)
• Table 24: Key Cross Of Marketed Drugs
• Table 25: XIPERE, Clinical Trial Description, 2024
• Table 26: YUTIQ/ ILUVIEN, Clinical Trial Description, 2024
• Table 27: HUMIRA, Clinical Trial Description, 2024
• Table 28: OZURDEX, Clinical Trial Description, 2024
• Table 29: RETISERT, Clinical Trial Description, 2024
• Table 30: Comparison of Emerging Drugs for Treatment
• Table 31: TRS01, Clinical Trial Description, 2024
• Table 32: Licaminlimab (OCS-02), Clinical Trial Description, 2024
• Table 33: Vamikibart (RO720220), Clinical Trial Description, 2024
• Table 34: OLUMIANT (baricitinib), Clinical Trial Description, 2024
• Table 35: EYS606, Clinical Trial Description, 2024
• Table 36: Izokibep, Clinical Trial Description, 2024
• Table 37: Brepocitinib, Clinical Trial Description, 2024
• Table 38: OCS-01, Clinical Trial Description, 2024
• Table 39: Key Market Forecast Assumptions for TRS01
• Table 40: Key Market Forecast Assumptions for Licaminlimab (OCS-02)
• Table 41: Key Market Forecast Assumptions for Vamikibart (RO720220/RG6179)
• Table 42: Total Market Size of Uveitis in the 7MM, in USD million (2020-2034)
• Table 43: Total Market Size of Uveitis by Therapies in the 7MM, in USD million (2020-2034)
• Table 44: Total Market Size of Uveitis in the US, in USD million (2020-2034)
• Table 45: The Market Size of Uveitis by Therapies in the US, in USD million (2020-2034)
• Table 46: Total Market Size of Uveitis in EU4 and the UK, in USD million (2020-2034)
• Table 47: The Market Size of Uveitis by Therapies in EU4 and the UK, in USD million (2020-2034)
• Table 48: Total Market Size of Uveitis in Japan, in USD million (2020-2034)
• Table 49: The Market Size of Uveitis by Therapies in Japan, in USD million (2020-2034)

List of Figures

• Figure 1: Classification of Uveitis
• Figure 2: Parts of the eye
• Figure 3: Anatomical Classification of Uveitis
• Figure 4: Etiological Classification of Uveitis
• Figure 5: Symptoms of Uveitis
• Figure 6: Standard Assessment in Uveitis
• Figure 7: Therapeutic Stepladder Algorithm in Uveitis
• Figure 8: Uveitis Treatment
• Figure 9: Therapeutic Algorithm
• Figure 10: Uveitis Patient Journey
• Figure 11: Total Diagnosed Prevalent Cases of Uveitis in the 7MM (2020-2034)
• Figure 12: Total Diagnosed Prevalent Cases of ME Associated with Uveitis in the 7MM (2020-2034)
• Figure 13: Total Diagnosed Prevalent Cases of Uveitis in the US (2020-2034)
• Figure 14: Type-specific Diagnosed Prevalent Cases of Uveitis in the US (2020-2034)
• Figure 15: Diagnosed Prevalent Cases of Uveitis by Anatomical Location in the US (2020-2034)
• Figure 16: Etiology-specific Diagnosed Prevalent Cases of Uveitis in the US (2020-2034)
• Figure 17: Total Diagnosed Prevalent Cases of Uveitis in EU4 and the UK (2020-2034)
• Figure 18: Type-specific Diagnosed Prevalent Cases of Uveitis in EU4 and the UK (2020-2034)
• Figure 19: Diagnosed Prevalent Cases of Uveitis by Anatomical Location in EU4 and the UK (2020-2034)
• Figure 20: Etiology-specific Diagnosed Prevalent Cases of Uveitis in EU4 and the UK (2020-2034)
• Figure 21: Total Diagnosed Prevalent Cases of Uveitis in Japan (2020-2034)
• Figure 22: Type-specific Diagnosed Prevalent Cases of Uveitis in Japan (2020-2034)
• Figure 23: Diagnosed Prevalent Cases of Uveitis by Anatomical Location in Japan (2020-2034)
• Figure 24: Etiology-specific Diagnosed Prevalent Cases of Uveitis in Japan (2020-2034)
• Figure 25: Total Market Size of Uveitis in the 7MM, in USD million (2020-2034)
• Figure 26: Total Market Size of Uveitis by Therapies in the 7MM, in USD million (2020-2034)
• Figure 27: Total Market Size of Uveitis in the US, in USD million (2020-2034)
• Figure 28: The Market Size of Uveitis by Therapies in the US, in USD million (2020-2034)
• Figure 29: Total Market Size of Uveitis in EU4 and the UK, in USD million (2020-2034)
• Figure 30: The Market Size of Uveitis by Therapies in EU4 and the UK, in USD million (2020-2034)
• Figure 31: Total Market Size of Uveitis in Japan, in USD million (2020-2034)
• Figure 32: The Market Size of Uveitis by Therapies in Japan, in USD million (2020-2034)
• Figure 33: SWOT Analysis of Uveitis
• Figure 34: Unmet Needs of Uveitis
• Figure 35: Health Technology Assessment
• Figure 36: Reimbursement Process in Germany
• Figure 37: Reimbursement Process in France
• Figure 38: Reimbursement Process in Italy
• Figure 39: Reimbursement Process in Spain
• Figure 40: Reimbursement Process in the United Kingdom
• Figure 41: Reimbursement Process in Japan

Key Highlights.

• The prevalence of uveitis has been increasing in the US due to the rising occurrence of uveitis-associated conditions, increasing awareness, and improved diagnosis of uveitis.
• Advancements in disease nomenclature for classification, clinical trials, drug delivery systems, multimodality diagnostic imaging, and laboratory testing involving "omics" technology have provided insight into disease pathogenesis. Moreover, insights into ocular immunology have also led to a better understanding of the molecular mechanisms that underlie etiology and susceptibility to uveitis.
• The ongoing research efforts are leading to a better understanding of uveitis risk factors, and treatment strategies, driving innovation in disease management.
• Corticosteroids are used as first-line therapy to treat inflammation in patients with uveitis. Further, immunomodulatory drugs are given as steroid-sparing agents when quiescence is not obtained with corticosteroids. Surgical interventions such as vitrectomy or the implantation of sustained-release devices are considered in extreme cases of uveitis.
• One of the major concerns in understanding the market for uveitis is that there is a lack of evidence to support the efficacy of many interventions used in the daily management of uveitis. Furthermore, no proper consensus guidelines are available in the US, EU4, and the UK, and Japan for managing different types of uveitis and its associated conditions.
• In 2022, the market size of uveitis was highest in the US among the 7MM, accounting for approximately USD 759.03 million, which is expected to increase by 2034.

DelveInsight's "Uveitis - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of uveitis, historical and forecasted epidemiology, as well as the uveitis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The uveitis market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM uveitis market size from 2020 to 2034. The report also covers current uveitis treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Uveitis Understanding and Treatment Algorithm

Uveitis Overview

Uveitis is a sight-threatening inflammatory disease affecting the middle uveal layer of the eye. The inflammation usually happens when the immune system fights an infection affecting the uveal tract (composed of the iris, choroid, and ciliary body) and adjacent structures (including the sclera, cornea, vitreous humor, retina, and optic nerve head).

Some common symptoms associated with uveitis include blurry vision with redness and sensation of pain, developing sensitivity to light, floaters in vision, and the presence of a white spot on the lower part of the eye. An individual's one eye or both may be affected. The pathophysiology of uveitis is not well understood; groups have hypothesized that trauma to the eye can cause cell injury or death, leading to the release of inflammatory cytokines leading to post-traumatic uveitis.

Uveitis Diagnosis

Uveitis is diagnosed after a complete evaluation of the past medical, family, and ophthalmic history of the patient. A full review of systems may also help identify a systemic disease with ocular manifestations. A visual acuity test, an ocular pressure test, and a slit lamp exam are performed by an ophthalmologist. The diagnosis and management of uveitis can be tricky for multiple reasons.

Further details related to country-based variations are provided in the report...

Uveitis Treatment

Treatment for uveitis aims to help reduce inflammation and relieve pain and discomfort in the eye, which can prevent permanent loss of vision or other complications. The primary goal of treating uveitis is getting rid of inflammation as fast as possible. Currently approved options include XIPERE, OZURDEX, HUMIRA, YUTIQ/ILUVIEN, RETISERT, and DUREZOL.

Uveitis Epidemiology

As the market is derived using a patient-based model, the uveitis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of uveitis, type-specific diagnosed prevalent cases of uveitis, diagnosed prevalent cases of uveitis by anatomical location, and etiology-specific diagnosed prevalent cases of uveitis, in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

• As per DelveInsight analysis, in 2022, there were approximately 1,009,025 diagnosed prevalent cases of uveitis in the 7MM.
• The total number of diagnosed prevalent cases of uveitis in the US was around 378,281 in 2022.
• The US contributed to the largest diagnosed prevalent uveitis population, acquiring ~37.5% of the 7MM in 2022. Whereas Spain accounted for the least, with around ~7% of the total population share, respectively, in 2022.
• In the US, patients diagnosed with noninfectious uveitis (NIU) are higher in number than infectious uveitis (IU). In 2022, there were nearly 344,587 cases of NIU, while IU accounted for around 33,695 cases. These numbers are expected to rise during the forecast period due to the rise of overall uveitis infection in the US.

According to DelveInsight estimates, in EU4 and the UK, based on anatomical location highest cases of uveitis were diagnosed in anterior uveitis, while intermediate uveitis has the least cases. In EU4 and the UK, anterior uveitis accounted for approximately 203,439, followed by 84,154 cases in posterior uveitis, 81,773 cases in pan uveitis, and 46,485 in intermediate uveitis in 2022, which are projected to increase during the forecast period.

• Japan accounted for approximately 214,892 diagnosed prevalent cases of uveitis, out of which nearly 8,039 cases were of HLA-B27-associated uveitis, 17,315 sarcoidosis, 9,894 Behcet's disease, 8,658 Vogt-Koyanagi-Harada disease, 618 JIA, 309 ankylosing spondylitis, 3,092 tuberculosis, 11,749 herpes, 81,628 idiopathic, and 73,589 others cases in 2022. These uveitis cases are expected to change during the forecast period in Japan (2023-2034).

Uveitis Drug Chapters

The drug chapter segment of the uveitis report encloses a detailed analysis of uveitis-marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also helps understand the uveitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

XIPERE: Clearside Biomedical/Bausch+Lomb

XIPERE, a triamcinolone acetonide injectable suspension, is the first approved medicine delivery via injection for suprachoroidal use to treat macular edema associated with uveitis in the US. Delivering the medicine to the suprachoroidal space (SCS) allows targeted delivery of the therapy with low levels elsewhere in the eye.

In October 2021, the US FDA approved XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use to treat macular edema associated with uveitis, a form of eye inflammation.

The recommended dosage is 4 mg (0.1 mL), administered as a suprachoroidal injection. It is a 40 mg/mL suspension in a single-dose glass vial with the supplied SCS microinjector.

Furthermore, the American Medical Association has granted a new permanent Category 1 Current Procedural Terminology (CPT) code for Bausch & Lomb's XIPERE to help facilitate better access and adoption of the product.

Note: Further marketed drugs and their details will be provided in the report...

Emerging Drugs

TRS01: Tarsier Pharma

TRS01, a lead product of Tarsier Pharmaceuticals, first in first-in-class topical immune modulator agent. Dazdotuftide (TRS) is a breakthrough platform technology for treating blinding ocular diseases. TRS was developed to 're-engineer' the immune system. The platform approaches inflammatory diseases from within the system. The technology can effectively treat various autoimmune and inflammatory ocular diseases. TRS01 is a polypeptide conjugate with a dual mechanism of action; the investigational agent induces anti-inflammatory macrophages and inhibits the nuclear factor-kB (Nf-kB) signaling pathway by toll-like receptor 4 (TLR4).

TRS01 has completed a Phase III trial, called TRS4Vision, in patients with active noninfectious anterior uveitis, including those with uveitis glaucoma. The trial met its secondary endpoint; however, it failed to meet the primary endpoint. Based on the safety and potency of the TRS01 and a positive Type C meeting with the US FDA, the company plans to initiate a second Phase III trial (Tarsier-04) for the treatment of noninfectious uveitis, including uveitic glaucoma with revised endpoints. Additionally, the company is developing TRS02 intravitreal injection for intermediate, posterior, or pan uveitis.

Note: Further emerging therapies and their detailed assessment will be provided in the final report.

Drug Class Insights

A severe intraocular inflammatory condition of the uveal tract known as uveitis frequently results in vision loss, blindness, and reduced quality of life. With the disease having a variable presentation, diagnosis and management are difficult. Treatment aims at obtaining quiescence of the disease, either by treating the infectious agent or treating the immune condition.

The current promising pharmacological classes for uveitis treatment include corticosteroids, immunosuppressants, and biologics.

Topical steroids like prednisolone 1% or dexamethasone 0.1% for anterior uveitis, mydriatic and cycloplegic agents to prevent the formation of posterior synechiae and for relieving photophobia and pain secondary to ciliary spasm are recommended. Difluprednate is recommended when there is posterior inflammation or macular edema. Systemic corticosteroids are typically reserved for bilateral uveitis, systemic disease, or when topical/local therapies fail to control inflammation; oral prednisone is the most commonly used drug. When the inflammation is severe, involving all the uveal layers and eventually the optic nerve, IV corticosteroids are needed to achieve ocular remission. Several intravitreal steroid injections are utilized in the treatment of uveitis. The approved products include YUTIQ, OZURDEX, XIPERE, RETISERT, and TRIESENCE. However, long-term corticosteroid treatment can cause serious systemic and ocular side effects, such as hypertension, diabetes, cataracts, and glaucoma.

Alternatively, immunomodulatory drugs are given as steroid-sparing agents when quiescence is not obtained with corticosteroids or in case of reactivation or new complications onset. These have good clinical results for systemic and ocular inflammatory diseases. It includes the antimetabolites (methotrexate, azathioprine, and mycophenolate mofetil); the calcineurin inhibitors (cyclosporine, tacrolimus, and sirolimus); alkylating agents (cyclophosphamide and chlorambucil). Despite these promising clinical results, it is used off-label for treating NIU. Refractory and recurrent uveitis require a combination of IMT agents. IMT is continued for 2 years while the patient is in remission before considering tapering medication.

These biologic response modifiers represent the next medications in the stepladder approach to noninfectious uveitis. Biologic response modifiers that include the tumor necrosis factor (TNF)-a inhibitors infliximab, adalimumab, etanercept, golimumab, and certolizumab; lymphocyte inhibitors include daclizumab, rituximab, abatacept, and basiliximab; specific receptor antagonists includes anakinra, canakinumab, gevokizumab, tocilizumab, alemtuzumab, efalizumab, secukinumab, and ustekinumab; and interferon (INF) treatments. While anti-TNF-a is the most widely used for treating uveitis. These medications are chosen, by adding or switching, when other immunosuppressive agents are ineffective. TNF-a is an important cytokine involved in ocular inflammation and tissue damage. Anti-TNF-a is also recommended for children. Adalimumab is a fully human anti-TNF-a monoclonal antibody approved for treating several immune-mediated inflammatory diseases, including noninfectious intermediate, posterior, and panuveitis. The lone approved product in this category, enjoying a major market share of biologics, is AbbVie's HUMIRA.

Uveitis Market Outlook

Uveitis is a serious intraocular inflammatory disorder of the uveal tract, often associated with visual impairment, blindness, and decreased quality of life. It often affects patients in their most active and economically productive years. It is the leading cause of preventable blindness worldwide and is a critically underserved disease in terms of treatment.

With the disease having a variable presentation, diagnosis and management are difficult. A prompt diagnosis, with the correct diagnostic approach and assessment of appropriate treatment, is extremely important to reduce inflammation and attain complete remission, thereby mitigating or avoiding ocular complications, permanent cumulative damage, and long-term vision loss. Treatment aims at obtaining quiescence of the disease, either by treating the infectious agent or treating the immune condition.

The recommended treatment scenario starts with the least aggressive treatments to induce inflammation remission and progresses to more aggressive treatments and, eventually, inflammation remission. The choice of therapy (including the administration route) depends on the underlying diagnosis, the aggressiveness of the disease, laterality, and the presence of comorbid conditions. It is also essential to balance the ability of these drugs to induce disease remission against their potential side effects and toxicities. Corticosteroids, immunomodulators, and biologics are the various treatment options besides surgery.

The current market has been segmented into different commonly used therapeutic classes based on the prevailing treatment pattern across the 7MM, which presents minor variations in the overall prescription pattern. YUTIQ/ILUVIEN, HUMIRA, and XIPERE are the major drugs covered in the forecast model.

Key players including RG6179, TRS01, OCS-02, OCS-01, EYS606, and others are evaluating their lead candidates in different stages of clinical development. They aim to investigate their products for the treatment of uveitis.

• The total market size of uveitis in the 7MM was approximately USD 1,468.66 million in 2022 and is projected to increase due to increasing awareness of the disease and the launch of the emerging therapies during the forecast period (2023-2034).
• According to DelveInsight's estimates, among the 7MM, the US had the largest market share for uveitis, with a revenue of USD 759.03 million in 2022, followed by Japan, Germany, and others.
• Among EU4 and the UK countries, Germany accounted for the maximum market size with approximately USD 115.73 million in 2022, while Spain occupied the bottom of the ladder with nearly USD 90.49 million in 2022.
• Japan accounted for the second largest market among the 7MM, with approximately USD 196.62 million in 2022, expected to increase during the forecast period (2023-2034).
• The current standard of care for uveitis includes corticosteroids like YUTIQ/ILUVIEN, XIPERE-for macular edema, immunosuppressants, biologics like HUMIRA, NSAIDs, and others. As per DelveInsight's estimates, in the 7MM, the second highest market share was captured by corticosteroids accounting for USD 344.78 million, out of which YUTIQ/ILUVIEN accounted for USD 32.34 million, while other corticosteroids accounted for USD 312.44 million, in 2022.
• The emerging pipeline is robust, and the major players involved are Tarsier Pharma (TRS01), Roche/Eleven Biotherapeutics (vamikibart (RO720220/RG6179)), Oculis Pharma (licaminlimab (OCS-02)), and others.
• Tarsier Pharma TRS01 is a topical immune modulator agent with the potential to treat active noninfectious anterior uveitis with or without uveitic glaucoma. It is expected to enter the US market by 2026 and is projected to generate a revenue of USD 2.91 million in its launch year.

Continued in report...

Uveitis Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2020-2034. For example, vamikibart (RO720220/RG6179), a monoclonal antibody, is being developed for a target patient pool having uveitic macular edema and is projected to enter EU4 and the UK in, 2027, is predicted to have a slow-medium uptake during the forecast period.

Further detailed analysis of emerging therapies drug uptake in the report...

Uveitis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I. It also analyzes key players involved in developing targeted therapeutics.

Pipeline development activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for emerging therapies for uveitis.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on uveitis evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Medical Professionals, Professors, Directors, and Others.

DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers like the University of California, University of Nebraska Medical Center Omaha, Johns Hopkins University School of Medicine, University Medical Center Schleswig Holstein, Sapienza University of Rome, and University of Tokyo School of Medicine were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or uveitis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Physician's View

According to our primary research analysis, several corticosteroids with different modes of action (topical, oral, or injections), some possessing more than one, are available in the market and prescribed as monotherapy or adjunctive therapy in different lines of treatment. Many cases can be successfully managed with prompt diagnosis and treatment, reducing vision loss and complications. However, some types of uveitis are chronic or recurrent, necessitating ongoing treatment and monitoring to preserve vision and avoid complications. As a result, each patient's treatment plan is tailored to their specific needs based on factors such as the type of uveitis, its frequency, etiology, and anatomical location, the person's age, and associated complications. For elderly patients, factors such as overall health, medication tolerance, and functional status are taken into account.

The current pipeline contains gene therapy, monoclonal antibodies, recombinant fusion proteins, and several small molecules that target different anti-inflammatory pathways in uveitis. The entry of these drugs will provide different options relating to patient-specific needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in uveitis trials, one of the most important primary outcome measures is the anterior chamber cell (ACC) grade.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Reimbursement of rare disease therapies can be limited due to lack of supporting policies and funding, challenges of high prices, lack of specific approaches to evaluating rare disease drugs given limited evidence, and payers' concerns about budget impact. The high cost of rare disease drugs usually has a limited impact on the budget due to the small number of eligible patients being prescribed the drug. The US FDA has approved several rare disease therapies in recent years. From a patient perspective, health insurance and payer coverage guidelines surrounding rare disease treatments restrict broad access to these treatments, leaving only a small number of patients who can bypass insurance and pay for products independently.

In June 2022, the CMS issued a product-specific J-Code for XIPERE (triamcinolone acetonide) effective July 1, 2022. J-Codes are reimbursement codes used by commercial insurers and government payers to identify therapies administered by a healthcare professional incident to the office visit. Issuing the permanent J-Code helped facilitate access to XIPERE for Americans suffering from macular edema associated with uveitis and helped streamline the reimbursement process. It became commercially available in March 2022. The new J-Code is J3299.

Blue Cross and Blue Shield of Alabama provide coverage for XIPERE (triamcinolone acetonide injectable suspension). The coverage is provided for 12 weeks and may be renewed.

In October 2018, the US FDA approved YUTIQ (fluocinolone acetonide intravitreal implant) to treat chronic noninfectious uveitis affecting the posterior segment of the eye. In July 2019, the CMS had assigned a specific and permanent reimbursement J-code, J7314, through the Healthcare Common Procedure Coding System (HCPCS) for YUTIQ, 0.18 mg 3-year micro-insert for chronic, noninfectious uveitis affecting the posterior segment of the eye. Furthermore, the code J7314 became effective in October 2019.

Patient assistance programs (PAPs) are usually sponsored by pharmaceutical companies and provide free or discounted medicines and copay programs to low-income, uninsured, and underinsured people who meet specific guidelines. Eligibility requirements vary for each program.

The YUTIQ developing company EyePoint Pharmaceuticals, Inc. provides EyePoint Assist HCP Portal that allows patients to conduct a benefits investigation, confirm insurance eligibility, and gain access to financial and reimbursement support.

OZURDEX is an intravitreal implant of 0.7 mg dexamethasone approved in the US in September 2010 for treating noninfectious uveitis affecting the posterior segment of the eye. Recognizing that reimbursement is a significant patient consideration, Allergan EyeCueSM provides a convenient and efficient way to help manage OZURDEX reimbursement processes. Through the OZURDEX saving program, eligible commercially insured patients may pay as little as USD 0 for OZURDEX.

An intravitreal implant RETISERT, for treating chronic noninfectious uveitis affecting the posterior segment, has a Medicare payment rate of almost USD 20,000 when used in a hospital outpatient setting, according to a press release from Bausch + Lomb. RETISERT (fluocinolone acetonide intravitreal implant) 0.59 mg was launched in the US in June, following approval by the FDA in April. The Centers for Medicare & Medicaid Services has designated the single-indication orphan drug eligible for Medicare pass-through payment under the hospital outpatient prospective payment system.

The European Union (EU) is the most biosimilar-friendly market, along with the European Economic Area countries (Iceland, Liechtenstein, and Norway), with the US vamping up its policies to align itself with its Trans-Atlantic neighbor. Biosimilar competition in Europe has brought about discounts to AbbVie's blockbuster immunosuppressant drug HUMIRA upwards of 80% during tendering. Overall, biosimilar uptake has increased in Europe because biologic "copycats" are cheaper, but full faith in these products is still required from physicians and patients.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenarios, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

The report provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenarios, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Further details will be provided in the report.

Scope of the Report:

• The report covers a segment of key events, an executive summary, descriptive overview of uveitis, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• Additionally, an all-inclusive account of the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will impact the current treatment landscape.
• A detailed review of the uveitis market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM uveitis market.

Uveitis Report Insights

• Patient Population
• Therapeutic Approaches
• Uveitis Pipeline Analysis
• Uveitis Market Size and Trends
• Existing and Future Market Opportunity

Uveitis Report Key Strengths

• 12 years Forecast
• The 7MM Coverage
• Uveitis Epidemiology Segmentation
• Key Cross Competition
• Attribute analysis
• Drugs Uptake and Key Market Forecast Assumptions

Uveitis Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions:

Market Insights

• What was the total market size of uveitis the market size of uveitis by therapies, and market share (%) distribution in 2020, and what would it look like by 2034? What are the contributing factors for this growth?
• How will TRS01 and licaminlimab (OCS-02) affect the treatment paradigm of uveitis?
• How will YUTIQ compete with upcoming products and marketed therapies?
• Which drug is going to be the largest contributor by 2034?
• What are the pricing variations among different geographies for approved and marketed therapies?
• How would future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of uveitis? What will be the growth opportunities across the 7MM concerning the patient population with uveitis?
• What is the historical and forecasted uveitis patient pool in the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan?
• Out of the above-mentioned countries, which country would have the highest diagnosed prevalent uveitis population during the forecast period (2023-2034)?
• What factors are factors contributing to the growth of uveitis cases?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for the treatment of uveitis? What are the current guidelines for treating uveitis in the US and Europe?
• How many companies are developing therapies for the treatment of uveitis?
• How many emerging therapies are in the mid-stage and late stage of development for treating uveitis?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What is the cost burden of current treatment on the patient?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of approved therapies?
• What is the 7MM historical and forecasted market of uveitis?

Reasons to Buy:

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the uveitis Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies for uveitis, barriers to accessibility of approved therapies (HUMIRA, YUTIQ/ILUVIEN, XIPERE, etc.), and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Uveitis Market Overview at a Glance

• 3.1. Market Share (%) Distribution of Uveitis in 2020
• 3.2. Market Share (%) Distribution of Uveitis in 2034

4. Methodology of Uveitis Epidemiology and Market

5. Executive Summary of Uveitis

6. Key Events

7. Disease Background and Overview of Uveitis

• 7.1. Introduction to Uveitis
• 7.2. Classification
• 7.3. Signs and Symptoms
• 7.4. Complications
• 7.5. Pathophysiology
• 7.6. Diagnosis
  • 7.6.1. Diagnosis Algorithm
  • 7.6.2. Diagnostic Guidelines
    • 7.6.2.1. American Academy of Family Physicians Recommendations for Uveitis Evaluation
    • 7.6.2.2. Diagnostic Recommendations From an Expert Committee
• 7.7. Treatment
  • 7.7.1. Treatment Algorithm
  • 7.7.2. Treatment Guidelines and Recommendations
    • 7.7.2.1. Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis- FOCUS Initiative
    • 7.7.2.2. American College of Rheumatology/Arthritis Foundation Guidelines for JIA Associated Uveitis (2019)
    • 7.7.2.3. Adalimumab and Dexamethasone for Treating Noninfectious Uveitis: NICE Guidelines

8. Patient Journey

9. Epidemiology and Patient Population

• 9.1. Key Findings
• 9.2. Assumption and Rationale
  • 9.2.1. Diagnosed Prevalent Cases of Uveitis
  • 9.2.2. Type-specific Cases of Uveitis
  • 9.2.3. Cases of Uveitis by Anatomical Location
  • 9.2.4. Etiology-specific Cases of Uveitis
  • 9.2.5. Cases of Macular Edema Associated With Uveitis
• 9.3. Total Diagnosed Prevalent Cases of Uveitis in the 7MM
• 9.4. Total Diagnosed Prevalent Cases of ME Associated with Uveitis in the 7MM
• 9.5. The US
  • 9.5.1. Total Diagnosed Prevalent Cases of Uveitis in the US
  • 9.5.2. Type-specific Diagnosed Prevalent Cases of Uveitis in the US
  • 9.5.3. Diagnosed Prevalent Cases of Uveitis by Anatomical Location in the US
  • 9.5.4. Etiology-specific Diagnosed Prevalent Cases of Uveitis in the US
• 9.6. EU4 and the UK
  • 9.6.1. Total Diagnosed Prevalent Cases of Uveitis in EU4 and the UK
  • 9.6.2. Type-specific Diagnosed Prevalent Cases of Uveitis in EU4 and the UK
  • 9.6.3. Diagnosed Prevalent Cases of Uveitis by Anatomical Location in EU4 and the UK
  • 9.6.4. Etiology-specific Diagnosed Prevalent Cases of Uveitis in EU4 and the UK
• 9.7. Japan
  • 9.7.1. Total Diagnosed Prevalent Cases of Uveitis in Japan
  • 9.7.2. Type-specific Diagnosed Prevalent Cases of Uveitis in Japan
  • 9.7.3. Diagnosed Prevalent Cases of Uveitis by Anatomical Location in Japan
  • 9.7.4. Etiology-specific Diagnosed Prevalent Cases of Uveitis in Japan

10. Marketed Drugs

• 10.1. Key Cross Competition
• 10.2. XIPERE: Clearside Biomedical/Bausch+Lomb
  • 10.2.1. Product Description
  • 10.2.2. Regulatory Milestones
  • 10.2.3. Other Development Activities
  • 10.2.4. Clinical Development
  • 10.2.5. Clinical Trials Information
  • 10.2.6. Safety and Efficacy
  • 10.2.7. Product Profile
• 10.3. YUTIQ/ILUVIEN: EyePoint Pharmaceuticals/Alimera Sciences
  • 10.3.1. Product Description
  • 10.3.2. Regulatory Milestones
  • 10.3.3. Other Development Activities
  • 10.3.4. Clinical Development
  • 10.3.5. Clinical Trials Information
  • 10.3.6. Safety and Efficacy
  • 10.3.7. Product Profile
• 10.4. HUMIRA: AbbVie/Eisai
  • 10.4.1. Product Description
  • 10.4.2. Regulatory Milestones
  • 10.4.3. Other Development Activities
  • 10.4.4. Clinical Development
  • 10.4.5. Clinical Trials Information
  • 10.4.6. Safety and Efficacy
  • 10.4.7. Product Profile
• 10.5. OZURDEX: AbbVie
  • 10.5.1. Product Description
  • 10.5.2. Regulatory Milestones
  • 10.5.3. Other Development Activities
  • 10.5.4. Clinical Development
  • 10.5.5. Clinical Trials Information
  • 10.5.6. Safety and Efficacy
  • 10.5.7. Product Profile
• 10.6. RETISERT: Bausch + Lomb
  • 10.6.1. Product Description
  • 10.6.2. Regulatory Milestones
  • 10.6.3. Other Development Activities
  • 10.6.4. Clinical Development
  • 10.6.5. Clinical Trials Information
  • 10.6.6. Safety and Efficacy
  • 10.6.7. Product Profile

11. Emerging Drugs

• 11.1. Key Cross Competition
• 11.2. TRS01: Tarsier Pharma
  • 11.2.1. Drug Description
  • 11.2.2. Other Developmental Activity
  • 11.2.3. Clinical Development
  • 11.2.4. Clinical Trials Information
  • 11.2.5. Safety and efficacy
  • 11.2.6. Product Profile
  • 11.2.7. Analysts' Views
• 11.3. Licaminlimab (OCS-02): Oculis Pharma
  • 11.3.1. Drug Description
  • 11.3.2. Other Development Activity
  • 11.3.3. Clinical Development
  • 11.3.4. Clinical Trials Information
  • 11.3.5. Safety and Efficacy
  • 11.3.6. Product Profile
  • 11.3.7. Analysts' Views
• 11.4. Vamikibart (RO720220/RG6179): Roche/Eleven Biotherapeutics
  • 11.4.1. Drug Description
  • 11.4.2. Other Developmental Activity
  • 11.4.3. Clinical Development
  • 11.4.4. Clinical Trials Information
  • 11.4.5. Safety and Efficacy
  • 11.4.6. Product Profile
  • 11.4.7. Analysts' Views
• 11.5. OLUMIANT (baricitinib): Eli Lilly and Company
  • 11.5.1. Drug Description
  • 11.5.2. Other Developmental Activity
  • 11.5.3. Clinical Development
  • 11.5.4. Clinical Trials Information
  • 11.5.5. Product Profile
  • 11.5.6. Analysts' Views
• 11.6. EYS606: Eyevensys
  • 11.6.1. Drug Description
  • 11.6.2. Other Developmental Activity
  • 11.6.3. Clinical development
  • 11.6.4. Clinical Trials Information
  • 11.6.5. Safety and Efficacy
  • 11.6.6. Product Profile
  • 11.6.7. Analysts' Views
• 11.7. Izokibep: Acelyrin/Affibody Medical
  • 11.7.1. Drug Description
  • 11.7.2. Other Developmental Activity
  • 11.7.3. Clinical Development
  • 11.7.4. Clinical Trials Information
  • 11.7.5. Product Profile
  • 11.7.6. Analysts' Views
• 11.8. Brepocitinib: Priovant Therapeutics
  • 11.8.1. Drug Description
  • 11.8.2. Other Developmental Activity
  • 11.8.3. Clinical Development
  • 11.8.4. Clinical Trials Information
  • 11.8.5. Product Profile
  • 11.8.6. Analysts' Views
• 11.9. OCS-01: Oculis Pharma
  • 11.9.1. Drug Description
  • 11.9.2. Clinical Development
  • 11.9.3. Clinical Trials Information
  • 11.9.4. Product Profile
  • 11.9.5. Analysts' views

12. Uveitis: Market Analysis

• 12.1. Key Findings
• 12.2. Key Market Forecast Assumptions
• 12.3. Market Outlook
• 12.4. Conjoint Analysis
• 12.5. Total Market Size of Uveitis in the 7MM
• 12.6. Total Market Size of Uveitis by Therapies in the 7MM
• 12.7. Market Size of Uveitis in the US
  • 12.7.1. Total Market Size of Uveitis in the US
  • 12.7.2. The Market Size of Uveitis by Therapies in the US
• 12.8. Market Size of Uveitis in EU4 and the UK
  • 12.8.1. Total Market Size of Uveitis in EU4 and the UK
  • 12.8.2. The Market Size of Uveitis by Therapies in EU4 and the UK
• 12.9. Market Size of Uveitis in Japan
  • 12.9.1. Total Market Size of Uveitis in Japan
  • 12.9.2. The Market Size of Uveitis by Therapies in Japan

13. Key Opinion Leaders' Views

14. SWOT Analysis

15. Unmet Needs

16. Market Access and Reimbursement

• 16.1. The United States
  • 16.1.1. Centre for Medicare & Medicaid Services (CMS)
• 16.2. In EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. The United Kingdom
• 16.3. Japan
  • 16.3.1. MHLW

17. Appendix

• 17.1. Bibliography
• 17.2. Acronyms and Abbreviations
• 17.3. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight